SwePub
Sök i LIBRIS databas

  Extended search

L773:1872 7913
 

Search: L773:1872 7913 > Antimicrobial resis...

  • Buhl, Michael E.J.Paracelsus Medical University (author)

Antimicrobial resistance surveillance of Bacteroides fragilis isolated from blood cultures, Europe, 2022 (ReSuBacfrag)

  • Article/chapterEnglish

Publisher, publication year, extent ...

  • 17 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:7657521c-1fc2-4d11-804c-c1d386f35f6f
  • https://lup.lub.lu.se/record/7657521c-1fc2-4d11-804c-c1d386f35f6fURI
  • https://doi.org/10.1016/j.ijantimicag.2024.107241DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • BackgroundBacteroides fragilis is the most frequent cause of anaerobic bacteraemia. Although recent data suggest a rise in antimicrobial resistance (AMR) of this and other anaerobic bacteria, surveillance remains limited due to a lack of both data availability and comparability. However, a newly introduced standardised method for antimicrobial susceptibility testing (AST) of anaerobic bacteria has made larger scale surveillance possible for the first time.AimTo investigate phenotypic AMR of Bacteroides fragilis isolates from bacteraemia across Europe in 2022.MethodsIn a multicentre approach, clinical microbiology laboratories in Europe were invited to contribute results of AST for Bacteroides fragilis blood culture isolates (including only the first isolate per patient and year). AST of a selection of four antibiotics was performed locally by participating laboratories in a prospective or retrospective manner, using the new EUCAST disc diffusion method on fastidious anaerobe agar (FAA-HB).ResultsA total of 16 European countries reported antimicrobial susceptibilities in 449 unique isolates of Bacteroides fragilis from blood cultures in 2022. Clindamycin demonstrated the highest resistance rates (20.9%, range 0 - 63.6%), followed by piperacillin-tazobactam (11.1%, 0 - 54.5%), meropenem (13.4%, 0 - 45.5%), and metronidazole (1.8%, 0 - 20.0%), all with wide variation between countries.ConclusionConsidering that the mean resistance rates across Europe were higher than expected for three of the four anti-anaerobic antibiotics under surveillance, both local AST of clinically relevant isolates of Bacteroides fragilis and continued surveillance on an international level is warranted.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sunnerhagen, TorgnyLund University,Lunds universitet,Infektionsmedicin,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Infection Medicine (BMC),Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Region Skåne(Swepub:lu)med-tsh (author)
  • Join-Lambert, OlivierUniversity Hospital Of Caen (author)
  • Morris, TreforUniversity Hospital of Wales (author)
  • Jeverica, SamoSlovenian National Laboratory of Health, Environment and Food (author)
  • Assous, Marc V.Hebrew University of Jerusalem (author)
  • Toprak, Nurver U.Marmara University Hospital (author)
  • Alcalá-Hernandez, LuisHospital Gregorio Maranon (author)
  • Lienhard, RetoADMed Microbiologie (author)
  • Veloo, Alida C.M.University Medical Center Groningen (author)
  • Cruz, HugoS. António General Hospital (author)
  • Sóki, JózsefUniversity of Szeged (author)
  • Novak, AnitaUniversity Hospital of Split (author)
  • Mazzariol, AnnaritaUniversity of Verona (author)
  • Wybo, IngridVrije Universiteit Brussel (VUB) (author)
  • Dumont, YannUniversity Hospital of Nancy (author)
  • Justesen, Ulrik s.Odense University Hospital (author)
  • Paracelsus Medical UniversityInfektionsmedicin (creator_code:org_t)
  • ReSuBacfrag 2022 study group, ESGAI

Related titles

  • In:International Journal of Antimicrobial Agents1872-7913

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view